New CAR-macrophages tested on patient-derived breast cancer organoids
Cohort Study to Determine the Antitumor Activity of New CAR-macrophages in Breast Cancer Patients' Derived Organoids (CARMA)
Centre Oscar Lambret · NCT05007379
This project will test whether newly developed CAR-macrophages can kill breast cancer cells grown in organoids made from patients' own tumor samples.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Sponsor | Centre Oscar Lambret (other) |
| Locations | 1 site (Lille) |
| Trial ID | NCT05007379 on ClinicalTrials.gov |
What this trial studies
This observational cohort collects tumor tissue and blood from adults with confirmed breast cancer who are undergoing surgery or biopsy. Tumor samples will be used to grow patient-derived organoids, three-dimensional tumor models that preserve features of each patient's cancer. Researchers will apply newly developed CAR-macrophages to these organoids to see whether the modified immune cells reduce tumor growth. Blood samples will be analyzed to characterize each patient's inflammatory status and to explore links between host factors and organoid responses.
Who should consider this trial
Good fit: Adults (18+) with histologically confirmed breast cancer of any stage who are scheduled for surgery or diagnostic tumor biopsy and who consent to donate tissue and blood are ideal candidates.
Not a fit: Patients who refuse biospecimen collection, whose tumors cannot be grown as organoids, or those seeking direct immediate treatment benefit are unlikely to receive personal therapeutic benefit from participation.
Why it matters
Potential benefit: If successful, this work could help identify CAR-macrophage approaches that more effectively kill individual patients' tumor cells and guide the development of personalized therapies.
How similar studies have performed: Preclinical studies using CAR-macrophages and patient-derived organoids have shown promising antitumor activity, but clinical evidence remains limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female aged 18 years or more * Histologically confirmed breast cancer at any stage * Requiring surgery or tumor biopsy as standard of care * Any or no systemic treatment * Signed informaed consent * Health insurance coverage Exclusion Criteria: * Opposed to biospecimen collection
Where this trial is running
Lille
- Oscar Lambret Center — Lille, France (RECRUITING)
Study contacts
- Study coordinator: Nawale HAJJAJI, MD PhD
- Email: n-hajjaji@o-lambret.fr
- Phone: +33 320295910
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Breast Cancer